What Is Gene Therapy?
Gene therapy is not one single treatment. It is a family of approaches that try to change what a cell is doing by changing the genetic instructions the cell receives. In rare disease, this often means delivering a working copy of a gene, reducing the effect of a harmful gene product, or using newer editing tools to correct or adjust DNA. The goal is not simply to treat symptoms from the outside, but to get closer to the root cause of a genetic disorder.
Plain-English explanation
Gene therapy is not one single treatment. It is a family of approaches that try to change what a cell is doing by changing the genetic instructions the cell receives. In rare disease, this often means delivering a working copy of a gene, reducing the effect of a harmful gene product, or using newer editing tools to correct or adjust DNA. The goal is not simply to treat symptoms from the outside, but to get closer to the root cause of a genetic disorder.
Why it matters
Many rare diseases begin with a change in a single gene. If researchers can safely reach the right cells and restore enough function, gene therapy could change the course of conditions that once had only supportive care. It also raises hard questions about safety, immune response, delivery, cost, access, and how long a benefit will last.
How it works
A gene therapy usually starts with a clear genetic target. Scientists decide which cells need to be reached, choose a delivery method such as an AAV vector or another platform, design the therapeutic payload, and test whether cells make the intended protein or change the intended pathway. Before a clinical trial, researchers need evidence on dose, tissue targeting, toxicity, immune response, manufacturing quality, and whether the measured effect is likely to matter for patients.
Key terms
Related interviews and articles
Dr. Guoping Feng (MIT) on SHANK3 Gene Therapy, Brain Disorders, and What’s Coming Next
Dr. Guoping Feng
Welcome — I’m Ron Kleiman, and this is GENEration Hope. In this episode, I’m joined by Dr. Guoping Feng, Professor of Neuroscience at MIT, affiliated with the McGovern Institute, the Yang Tan Collective, and the Broad Institute. 
Dr. Alex Kolevzon on Gene Therapy, SHANK3 & the Future of Treatment
Dr. Alexander Kolevzon
Welcome to Generation Hope. In this wide-ranging interview, Dr. Alex Kolevzon (Mount Sinai) sits down with Ron to discuss the science, the trials, and the human side of gene therapy for rare neurodevelopmental disorders. In this episode...
What AI Drug Discovery Could Mean for Rare Disease Families
AI drug discovery is entering a new phase: not just better software, but a new industrial stack linking frontier models, pharma data, robotics, and real experiments.
Why it matters: Rare disease research often starts with small datasets, limited funding, urgent timelines, and difficult trial design. AI-linked discovery systems could help researchers generate stronger candidates and better experiments faster, but families should watch for clinical validation, access, manufacturing, and clear evidence rather than hype.
Source: GENEration Hope editorial analysis